CMPX

NASDAQ open

Compass Therapeutics

0.66 USD
▼-0.02-3.07%
盘后 0.70 0.00%
2026-11-20
市值
$123.94M
市盈率
—
EPS
-0.46
股息率
—
52 周区间
0.57 – 6.88
成交量
889.46K
Beta
1.06
目标价
5.26
52W 低 0.5752W 高 6.88
价格走势

公司简介

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; C...